Glucagon‐Like Peptide‐1 Receptor Agonists in Type 1 Diabetes: The Importance of Identifying the Insulin‐Resistant Type 1 Diabetes Phenotype, and Differentiating Early and Newer Generation Therapies

Jerry R. Greenfield, Ruth Frampton, Jennifer R. Snaith

doi:10.1111/dom.71505

CrossrefKarta ta’ informazzjoni

Glucagon‐Like Peptide‐1 Receptor Agonists in Type 1 Diabetes: The Importance of Identifying the Insulin‐Resistant Type 1 Diabetes Phenotype, and Differentiating Early and Newer Generation Therapies

Jerry R. Greenfield, Ruth Frampton, Jennifer R. Snaith

Diabetes, Obesity and Metabolism · 2026-11-03

DOI: 10.1111/dom.71505 ↗

Astratt Dettalji biblijografiċi

Astratt

Ebda abstract disponibbli.

Dettalji biblijografiċi

Awturi/Awturiċi: Jerry R. Greenfield, Ruth Frampton, Jennifer R. Snaith
Ġurnal: Diabetes, Obesity and Metabolism
Sena tal-pubblikazzjoni: 2026
Pubblikatur: Wiley
DOI: 10.1111/dom.71505
ISSN: 1462-8902; 1463-1326
Sors: Crossref

Għarfien li jaqbel max-xogħol tiegħek.

Minn bidu b’xejn u riċerka personali tal-letteratura sal-Research Suite sħiħa.

Ara t-tariffi →

Il-full texts kollha tal-pubblikaturi huma inklużi?

Le. Ir-referenzi biblijografiċi, l-astratti u t-testi sħaħ huma kontenuti differenti. Jekk test sħiħ huwiex disponibbli jiddependi mis-sors, Open Access u l-liċenzji eżistenti tiegħek. Pjan ta’ EUVIMED ma jissostitwix drittijiet addizzjonali tal-pubblikaturi.